8-K - Prelude Therapeutics Incorporated | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Prelude Therapeutics Incorporated issued a press release on March 10, 2026, announcing its financial results and financial condition under Item 2.02. The company also prepared investor presentation materials under Item 7.01 to be used in investor communications.

Key Takeaways

1Press release dated March 10, 2026 (Exhibit 99.1)

2Investor presentation materials (Exhibit 99.2)

3Item 2.02: Results of Operations and Financial Condition disclosed

4Item 7.01: Regulation FD Disclosure of investor presentation

5Filing date: 2026-03-10

Current Report Details

Event Type

Financial Results

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition. On March 10, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financ

Financial Results

7.01

Regulation FD Disclosure. The Company has prepared investor presentation materials with information about the Company, which it intends to use as part of invest

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 10, 2026 99.2 Presentation 104 Cover Page Interactive

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2